Cue Biopharma, Inc. Debt Disclosure

5. Loan with First Citizens Bank (formerly with Silicon Valley Bank)

On February 15, 2022 (the “Closing Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”), with Silicon Valley Bank, as lender (“SVB”). The Company drew $10,000,000 in term loans under the Loan Agreement (the "Term Loans") on the Closing Date. The Loan Agreement was amended in April 2023 and October 2024.

The Term Loans bear interest at a floating rate per annum equal to the greater of (A) the prime rate (as published in the money rates section of The Wall Street Journal) plus 2.25% and (B) 5.50%. The Term Loans were interest only from the Closing Date through June 30, 2023, after which the Company is required to pay 30 equal monthly installments of principal. At December 31, 2024, the interest rate was 10.00% which is based on the prime rate plus 2.25%.

The Term Loans may be prepaid in full with payment of a 1.00% prepayment premium. Upon prepayment or repayment in full of the Term Loans, the Company will be required to pay a one-time final payment fee equal to 5.00% of the original principal amount of any funded Term Loans being repaid. This one-time final payment fee is recorded to interest expense using the effective interest method over the period of the Term Loans in the consolidated statements of operations and comprehensive loss.

The Term Loans and related obligations under the Loan Agreement are secured by substantially all of the Company’s properties, rights and assets, except for its intellectual property which is subject to a negative pledge under the Loan Agreement.

The Loan Agreement, as amended, contains customary representations, warranties, events of default and covenants. In addition to the foregoing, the Company is required to have at all times on deposit in accounts of the Company maintained with SVB, unrestricted and unencumbered cash in an amount equal to the lesser of (i) 100% of the dollar value of the Company’s consolidated cash, in the aggregate, at all financial institutions and (ii) $20,000,000. On March 10, 2023, SVB was closed and the Federal Deposit Insurance Corporation (the “FDIC”) was appointed receiver for the bank. The FDIC created a successor bridge bank, and all deposits and loans of SVB were transferred to the bridge bank under a systemic risk exception approved by the United States Department of the Treasury, the Federal Reserve and the FDIC. On March 27, 2023, First Citizens Bank & Trust Company (“First Citizens Bank”), assumed all of SVB’s deposits and certain other liabilities and acquired substantially all of SVB’s loans and certain other assets from the FDIC. First Citizens Bank continues to hold the Company’s Term Loans under the same existing terms and covenants which were in place with SVB.

During the years ended December 31, 2024 and 2023, the Company recognized interest expense related to the Term Loans of $0.6 million and $1.0 million, respectively. For both the years ended December 31, 2024 and 2023, the Company

recognized interest expense related to accretion of the final repayment of $0.1 million. As of December 31, 2024 the Company has recorded a short term liability for the net remaining balance due on the loans of $4.0 million. The loans are due to be paid in full by December 1, 2025.

Debt Issuance Costs

The Company incurred a total of $142,000 in debt issuance costs upon entering into the Loan Agreement. Debt issuance costs are deferred, presented as a reduction of debt, and are amortized using the effective interest rate method over the term of the loan. For both the years ended December 31, 2024 and 2023, the Company recorded approximately $37,000 in amortization of debt issuance costs to interest expense in the consolidated statements of operations and comprehensive loss. At December 31, 2024, the Company recorded the $37,000 of debt issuance costs to short term contra-liabilities.

As of December 31, 2024 the Company recorded a $4.3 million short term liability consisting of the net remaining balance due on the loans of $4.0 million, plus $370,000 of accretion of the final payment, less $37,000 of unamortized issuance costs. The loans are due to be paid in full by December 1, 2025.